Overview

A Study of the Efficacy of Prolonged-Release Melatonin Versus Placebo in Diabetic Patients Suffering From Insomnia

Status:
Completed
Trial end date:
1997-03-01
Target enrollment:
Participant gender:
Summary
Objective - Type 2 uncontrolled diabetic patients often have low endogenous melatonin and suffer from sleep disorders. The effect of a prolonged-release melatonin (PRM) formulation on glucose lipid metabolism and sleep is studied in type 2 diabetes patients with insomnia.
Phase:
Phase 2
Details
Lead Sponsor:
Neurim Pharmaceuticals Ltd.
Treatments:
Melatonin